Alkermes presents real-world study comparing Lybalvi versus olanzapine adherence, relapse proxies

• Alkermes flagged new real-world studies on LYBALVI and ARISTADA, with results already presented at spring 2026 psychiatry and health-economics conferences.
• Real-world analyses comparing LYBALVI with olanzapine pointed to stronger treatment adherence and persistence, with fewer relapse-related acute-care events such as hospitalizations or emergency-room visits.
• A separate study in young adults showed a reduction in relapse proxies in the year following LYBALVI initiation versus the prior year.
• The disclosures add post-launch evidence aimed at supporting LYBALVI’s positioning in schizophrenia and bipolar I disorder, with an emphasis on outcomes tied to utilization and continuity of care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260521770348) on May 21, 2026, and is solely responsible for the information contained therein.